Cargando…
922. Cost-effectiveness of baloxavir marboxil versus oseltamivir or no treatment for the management of influenza in the United States
BACKGROUND: Influenza poses a significant burden that can be effectively mitigated with antivirals. Baloxavir marboxil is an oral, single dose first-in-class endonuclease inhibitor that improves influenza symptoms and rapidly reduces virus shedding, shortening the infectious period and potentially r...
Autores principales: | Hansen, Svenn, Cheng, Shih-Chen, Surinach, Andy, Yau, Vince, Best, Jennie H, Zaraket, Hassan, Zhou, Hao, Zumofen, Marie-Helene Blanchet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679070/ http://dx.doi.org/10.1093/ofid/ofad500.967 |
Ejemplares similares
-
1518. Real-World Comparative Effectiveness of Baloxavir Marboxil versus Oseltamivir on Influenza-Related Complication and Resource Utilization
por: Neuberger, Eddie, et al.
Publicado: (2020) -
Efficacy of baloxavir marboxil on household transmission of influenza infection
por: Umemura, Takumi, et al.
Publicado: (2020) -
Baloxavir Marboxil: An Original New Drug against Influenza
por: Dufrasne, François
Publicado: (2021) -
Early Fever Resolution in Early Childhood Influenza Treated with Baloxavir Marboxil: A Retrospective Study Compared to Those with Oseltamivir
por: Nezu, Keiko, et al.
Publicado: (2023) -
Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil
por: Omoto, Shinya, et al.
Publicado: (2018)